Investigators at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have demonstrated that in the liver, some endothelial cells (ECs) acted as antigen-presenting cells of sorts. These lipoprotein lipase (LPL)-expressing cells cross-presented tumor antigens on their surface, alerting T cells to the presence of metastases. Read More
The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell therapeutics emerging as the dark horse in what speakers at BIO Asia-Taiwan 2026 described as CAR T’s second revolution. Read More
Akari Therapeutics plc has established a strategic research collaboration with Whitehawk Therapeutics Inc. to conduct preclinical studies evaluating Akari’s proprietary PH1 spliceosome-modulating payload technology in combination with Whitehawk’s topoisomerase I inhibitor antibody-drug conjugate platform. Read More
The Foundation for Angelman Syndrome Therapeutics (FAST) has awarded a 2-year grant to Frances Arnold, PhD, winner of the 2018 Nobel Prize in Chemistry, to develop new molecular tools that could help advance future RNA-targeted therapeutics for Angelman syndrome. Read More
Researchers from Ractigen Therapeutics Co. Ltd. described the preclinical profile of RAG-17, an siRNA therapy designed to knockdown the expression of SOD1, conjugated to a smart chemistry aided delivery (SCAD) system for enhanced CNS delivery via intrathecal injection. Read More
Breezebio Inc. (formerly Genedit Inc.) has entered into a joint research agreement with Ligachem Biosciences Inc. to develop innovative cancer vaccine therapies. Read More
Etern Therapeutics (Wuxi) Co. Ltd. has synthesized new TNF-α inhibitors potentially useful for the treatment of rheumatoid arthritis, Alzheimer’s disease, cachexia, Blau syndrome, Crohn’s disease, ulcerative colitis, multiple sclerosis and psoriasis, among others. Read More
Hinova Pharmaceuticals Inc. has patented new molecular glue degraders comprising E3 ubiquitin-protein ligase binding agents acting as proto-oncogene Vav (VAV1) degradation inducers. As such, they are reported to be potentially useful for the treatment of autoimmune diseases, inflammatory disorders and cancer. Read More
Conventional transplantation approaches using neural progenitors have emerged as a potential alternative for stroke treatment, but their efficacy is limited by poor survival and insufficient migration and integration in the post-stroke environment. Read More
Shanghai Yogar Therapeutics Co. Ltd. has divulged new apelin (APJ) receptor agonists potentially useful for the treatment of heart failure, pulmonary hypertension and muscle atrophy. Read More
Mediboston Biologics Co. Ltd. has disclosed new antibody-drug conjugates comprising an antibody or antigen-binding fragment covalently linked to a camptothecin derivative potentially useful for the treatment of cancer. Read More
Researchers from Sun Yat-sen University Cancer Center reported the preclinical characterization of YM-1240, a novel EZH2/HDAC dual inhibitor in models of lymphoma. Read More
